Related Experiment Video
Updated: Jul 26, 2025
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Case report: Regression of Glioblastoma after flavivirus infection
Patricia P Garcez1, André Guasti2,3, Nina Ventura2,4
1Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
Abstract:
Glioblastoma is the most frequent and aggressive primary brain cancer. In preclinical studies, Zika virus, a flavivirus that triggers the death of glioblastoma stem-like cells. However, the flavivirus oncolytic activity has not been demonstrated in human patients. Here we report a glioblastoma patient who received the standard of care therapy, including surgical resection, radiotherapy and temozolomide. However, shortly after the tumor mass resection, the patient was clinically diagnosed with a typical arbovirus-like infection, during a Zika virus outbreak in Brazil. Following the infection resolution, the glioblastoma regressed, and no recurrence was observed. This clinical response continues 6 years after the glioblastoma initial diagnosis.
Insights
A Zika virus infection led to the regression of aggressive glioblastoma in a patient. This suggests potential oncolytic activity of Zika virus in human glioblastoma treatment.
Area of Science:
- Neuro-oncology
- Virology
- Immunology
Background:
- Glioblastoma is the most aggressive primary brain tumor.
- Preclinical studies suggest Zika virus can kill glioblastoma stem cells.
- Oncolytic activity of Zika virus in humans remains unproven.
Observation:
- A glioblastoma patient experienced a Zika virus infection during a Brazil outbreak.
- The patient had undergone standard glioblastoma treatment (surgery, radiotherapy, temozolomide).
- Following infection recovery, the patient's glioblastoma showed significant regression.
Findings:
- The patient has remained recurrence-free for 6 years post-infection and treatment.
- This case provides the first clinical evidence of Zika virus's oncolytic effect in human glioblastoma.
- The flavivirus infection appears to have contributed to long-term tumor control.
Implications:
- Zika virus may represent a novel therapeutic agent for glioblastoma.
- Further research into flavivirus oncolytic therapy for brain tumors is warranted.
- This finding opens new avenues for treating aggressive brain cancers.
